UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease

Phase 2

Terminated

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Recurrent Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)

Interventions: Drug: clofarabine
Drug: cytarabine
Biological: filgrastim

First Posted Date: 2009-03-18

Last Posted Date: 2017-05-15

Lead Sponsor: University of Washington

Target Recruit Count: 2

Registration Number: NCT00863434

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Immunologic Effects of Echinacea

Not Applicable

Completed

Conditions: Upper Respiratory Tract Infections

Interventions: Biological: Echinacea purpurea
Drug: placebo

First Posted Date: 2009-03-12

Last Posted Date: 2018-05-01

Lead Sponsor: University of Washington

Target Recruit Count: 20

Registration Number: NCT00860795

Locations: 🇺🇸
Bastyr University, Kenmore, Washington, United States

Homeopathic Cold Medicine for Children

Not Applicable

Completed

Conditions: Upper Respiratory Tract Infection

Interventions: Drug: Hyland's Cold 'n Cough 4 Kids

First Posted Date: 2009-03-09

Last Posted Date: 2018-07-26

Lead Sponsor: University of Washington

Target Recruit Count: 50

Registration Number: NCT00858494

Locations: 🇺🇸
University of Washington Medical Center-Roosevelt Pediatric Care Center, Seattle, Washington, United States

Diagnostic Accuracy of Multislice CT Angiography for Acute Chest Pain

Completed

Conditions: Acute Coronary Syndrome
Chest Pain
Pulmonary Embolism
Aortic Dissection

First Posted Date: 2009-03-04

Last Posted Date: 2017-11-27

Lead Sponsor: University of Washington

Target Recruit Count: 102

Registration Number: NCT00855231

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

Early Intervention in Pulmonary Exacerbation in Cystic Fibrosis

Not Applicable

Completed

Conditions: Cystic Fibrosis

Interventions: Other: Early Intervention

First Posted Date: 2009-02-25

Last Posted Date: 2016-12-01

Lead Sponsor: University of Washington

Target Recruit Count: 42

Registration Number: NCT00850551

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

Phase 1

Terminated

Conditions: Refractory Multiple Myeloma
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: cyclophosphamide
Drug: pegylated liposomal doxorubicin hydrochloride
Drug: bortezomib
Drug: dexamethasone

First Posted Date: 2009-02-23

Last Posted Date: 2017-09-08

Lead Sponsor: University of Washington

Target Recruit Count: 31

Registration Number: NCT00849251

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant

Phase 1

Completed

Conditions: Localized Unresectable Adult Primary Liver Cancer
Localized Resectable Adult Primary Liver Cancer
Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer

Interventions: Drug: sorafenib tosylate
Other: laboratory biomarker analysis

First Posted Date: 2009-02-16

Last Posted Date: 2015-03-27

Lead Sponsor: University of Washington

Target Recruit Count: 4

Registration Number: NCT00844168

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Oral T7 Oral Testosterone in Man

Phase 2

Completed

Conditions: Healthy Males
Male Contraceptive

Interventions: Drug: First Intervention (7 days)
Drug: Second Intervention (7 days)
Drug: Third Intervention (7 days)
Other: First Washout (7 days)
Other: Second wash-out period

First Posted Date: 2009-02-12

Last Posted Date: 2014-01-13

Lead Sponsor: University of Washington

Target Recruit Count: 11

Registration Number: NCT00842751

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Peripheral Immunologic Response of Solid Organ Transplant Recipients to Depletion Versus Non-depletion Protocols

Completed

Conditions: Liver Disease
Liver Transplantation

Interventions: Procedure: blood sampling

First Posted Date: 2009-02-09

Last Posted Date: 2011-03-03

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT00839709

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone

Phase 1

Completed

Conditions: Healthy Males

Interventions: Drug: Acyline
Other: placebo hCG (no active ingredient)
Drug: hCG (human chorionic gonadotropin)
Drug: Testosterone gel

First Posted Date: 2009-02-09

Last Posted Date: 2016-01-11

Lead Sponsor: University of Washington

Target Recruit Count: 59

Registration Number: NCT00839319

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy